Hartaj Singh

BTIG initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) Monday with a Buy rating and $5.50 price target. Analyst Hartaj Singh believed the “current valuation reflects the Street assuming a 15-20 percent probability of vosaroxin approval in the US and EU. We believe the...

BTIG initiated coverage on United Therapeutics Corporation (NASDAQ: UTHR) Monday with a Neutral rating. Analyst Hartaj Singh believed a “late-2017 patent cliff for 3 out of 4 of its top products that could reduce 2018 adjusted EPS to 2013 levels (~$6-7/share) is offset by the blue sky...

BTIG initiated coverage on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Monday with a Buy rating and $200 price target. Analyst Hartaj Singh believed “that [the] current valuation is not indicative of the significant potential for combination Kalydeco/lumacaftor therapy in cystic...